SLC5A2 and type 1 diabetes mellitus: Although there is no established phenotype in type 2 diabetes concerning SGLT-2 inhibitor-associated EDKA, it appears that those with poorer β cell function reserve [37], longer duration of diabetes, poorer control of diabetes, and lower BMI are more susceptible to EDKA [38], not to mention the type 1 diabetes [39].